Serum levels of cellular mediators that drive inflammation in RA, such as interleukin-6 and tumor necrosis factor alfa (TNF-α), decreased after the first MSCs treatment without evidence of toxicity at the dosage concentration in a period studied. Here, TNF is linked to rheumatoid arthritis.